Udenyca
About Udenyca
Udenyca is a Healthcare company, and was acquired by Intas in December 2024. Developer of a prescription medicine to reduce infection risk in cancer patients. Its website udenyca.com draws about 31 thousand monthly visits. Its focus areas include Pharmaceutical Product Websites. Its legal entity is Coherus BioSciences, Inc.
Company details
Biosimilar pegfilgrastim products are developed by Udenyca in the biotechnology sector. These medicines are designed to mitigate neutropenia-related infections in patients undergoing chemotherapy for cancer. Administration options include prefilled syringes and on-body injectors for ease of use. Support services are offered to patients, encompassing educational resources and treatment guidance. Safety data and prescribing details are provided through official channels, with operations centered in the United States pharmaceutical market.
- Stage Acquired
- SectorsHealthcare
- Website udenyca.com
- Acquired by Intas (Dec 2024)
- Legal Name Coherus Biosciences, Inc
Investors in Udenyca
Udenyca has secured backing from 1 investor. Prominent investors backing the company include Intas.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Formulation development, drug manufacturing, and marketing services are provided. | 1977 | intaspharma.com | Ahmedabad, India |
Investor details for Udenyca
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Web traffic of Udenyca
The website of Udenyca (udenyca.com) receives about 30.6K visits a month.
- Monthly visits30.6K
▼ 8.8% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Udenyca
Complete news archive for Udenyca
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Udenyca
Biosimilar pegfilgrastim products are developed by Udenyca in the biotechnology sector. These medicines are designed to mitigate neutropenia-related infections in patients undergoing chemotherapy for cancer. Administration options include prefilled syringes and on-body injectors for ease of use. Support services are offered to patients, encompassing educational resources and treatment guidance. Safety data and prescribing details are provided through official channels, with operations centered in the United States pharmaceutical market.
Udenyca has 1 investor. Key investors include Intas.
Udenyca operates through Coherus Biosciences, Inc.
Yes. Udenyca was acquired by Intas in December 2024.